IDL Diagnostics
IDL Diagnostics is a Swedish in vitro diagnostics company focused on biomarker-based tests for urology and bacteriology. Its portfolio includes rapid tests, laboratory assays, and products designed for automated platforms, with operations conducted through its subsidiary IDL Biotech and supporting entities in the group.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueTests used to detect and monitor urological disease, including bladder cancer biomarkers.
Assays for identifying bacterial infections and supporting clinical decision-making.
Tests designed for use on automated readers and partner platforms in clinical labs.
Additional biomarker-based products and development-stage diagnostic offerings.
Customers
IDL Diagnostics sells to healthcare and laboratory customers that need reliable biomarker tests for early detection and follow-up of disease. Its products are used in clinical settings, including hospitals, laboratories, and partner-led diagnostic channels, with emphasis on urology, infection, and oncology applications. The company also works through distributors and platform partners in international markets, where registration and market access are important buying criteria.
Buy UBC and related tests for early detection and monitoring of disease in clinical care pathways.
Use ELISA and bacteriology assays for routine testing and diagnostic workflows.
Buy or license products to commercialize them in local markets and on automated readers.
Influence adoption by selecting tests that improve early diagnosis and follow-up.
Strategy
IDL Diagnostics is focused on expanding sales of its existing biomarker tests while securing registrations and market access in new priority countries. The company is also developing automated-platform offerings and partnerships so its products can reach broader clinical workflows and larger addressable markets.
Diagnostics growth depends on local registrations, distribution, and clinical adoption in new countries.
Platform-compatible tests can scale through installed readers and partner channels.
New biomarkers and improved assays support broader clinical use and future growth.
Geography
IDL Diagnostics is headquartered in Stockholm, Sweden, and its operational activities are run through IDL Biotech. The company serves existing markets in Europe and is actively building presence in new international markets, including China and the Middle East through partners and joint ventures. Geography matters because market access, registrations, and local distribution relationships are central to selling diagnostics outside the home market.
Risks
IDL Diagnostics depends on regulatory approvals, clinical adoption, and distributor execution to convert its biomarker portfolio into sales. The business is also exposed to competition from other IVD providers, reimbursement and procurement pressure, and the risk that new products or market entries take longer than expected.
New markets require product approvals and studies before commercialization.
Exposure: UBC and TK1 launch plans in China
A meaningful part of international growth relies on third-party commercialization.
Alternative diagnostics and larger competitors can limit market share gains.
Hospitals and labs may adopt new tests slowly without clear workflow benefits.
Exposure: Automated-platform and biomarker products
Accounting
Judgemental itemsThe group has transitioned from Swedish K3 to IFRS, affecting comparability across periods.
Impact: Equity, profit, and balance sheet presentation may differ from earlier reports
Diagnostic product development can create intangible assets that must be tested for recoverability.
Impact: Impairment charges could affect earnings and asset values
Right-of-use assets and lease liabilities change expense classification and leverage presentation.
Impact: Operating expenses and finance costs are split differently under IFRS 16
Sales through distributors, platform partners, and market launches can create timing differences.
Impact: Quarterly revenue may be uneven depending on shipment and acceptance timing
Similar listed companies
Publicly listed companies with a comparable business focus.
Insight Molecular Diagnostics Inc.
IMDX · In Vitro & In Vivo Diagnostic Substances
IDEXX Laboratories, Inc
IDXX · In Vitro & In Vivo Diagnostic Substances
IDEXX Laboratories develops and sells diagnostic products and services for veterinarians, livestock producers, water testing customers, and selected human point-of-care uses.
Boule Diagnostics
BOUL · Health Care
Boule Diagnostics AB is a global diagnostics company specializing in near-patient, decentralized blood diagnostics.
Biodesix, Inc
BDSX · Services-Medical Laboratories
Biodesix is a U.S.-based diagnostic solutions company focused on lung disease testing and diagnostic development services.
Onconetix, Inc.
ONCO · Pharmaceutical Preparations
IDEAYA Biosciences, Inc.
IDYA · Pharmaceutical Preparations
IDEAYA Biosciences is a clinical-stage precision oncology company focused on discovering and developing targeted cancer therapies matched to specific molecular alterations.
Last updated: 24/09/2026